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Particle Characterisation in Drug Delivery 
 
 
Introduction 
The use of materials in the nano-scale dimensions is a proving to be a promising approach to 
overcome drug delivery challenges. ‘Nanomedicine’ technologies are gradually achieving 
commercial success and reaching the clinic 1. Sub-micron nanocarriers have the potential to 
ferry the therapeutic to its site of action and in this process overcome the biological barriers 2-3 
and achieve targeted drug delivery, controlled or stimuli-responsive delivery and protect the of 
therapeutic from biological milieus. Many different types of nanocarriers have been described, 
including polymeric nanoparticles (NPs), liposomes, solid lipid NPs, micelles, dendrimers and 
metal NPs among other systems (the terms ‘nanomedicine’, ‘NP’ and ‘nanocarriers’ are used 
herein to describe all nanosystems). Of particular interest are nanocarriers with the ability to 
act selectively and target cell internalisation processes, guiding the therapeutic into 
subcellular regions. NP features important in dictating their drug delivery performance, 
including targeted delivery and cellular trafficking, are their size, shape and surface 
characteristics such as surface charge, chemistry and the distribution of ligands.  
 
Why NP characterisation matters in drug delivery 
NPs can be fabricated from different materials with different physical and chemical properties. 
In addition, they can be surface decorated with a range of ligands in order to enhance their 
therapeutic response (e.g. improving targeting or reducing immune response) or chemical 
groups that improve NPs stability. This is shown in Figure 1. As a result, a huge number of 
combinations of NP parameters are possible, with the idea of tailoring these systems for 
specific applications. As mentioned above, the interdependent effect of NP size, shape, 
composition and surface chemistry is crucial in dictating their interaction with cells and 
therefore drug delivery capability. 
 
 
 
Figure 1. Nanomedicine design. Nanocarriers can be fabricated from different materials with different 
physical and chemical properties. These can be surface functionalised with a range of ligands and 
chemical groups offering stability. Figure taken from Chou et al. 4.  
 
 
Considering NP size, it has been shown that this parameter affects the cell uptake efficiency 
and kinetics. Size-dependent uptake in different cell lines has been observed for metal 5-7, 
mesoporous silica 8 and polystyrene NPs 9, with the maximum efficiency at a NP core size in 
the range of 30–50 nm 10. The effect of size on NP cell uptake and also transepithelial 
transport was also shown for systems displaying ligands targeting transcytosis systems 11. NP 
size also affects tissue distribution and elimination 12, as well as cytotoxicity 13. 
 
Surface charge is also an important factor determining the fate of NP interaction with the 
biological systems. In terms of cell uptake, positively charged NP penetrate the cell 
membranes and internalise with the greatest efficiency compared to neutral and negatively 
charged particles 14, probably due to binding to negatively charged groups on the cell surface. 
However, positively charged particles are also considerably more toxic compared to 
negatively charged systems 14. 
 
Clearly, the biological response of nanomedicines relies heavily on their specific 
physicochemical characteristics. This is important as for this class of therapeutics the 
biological effect generated depends not only on the action of the active therapeutic(s) 
incorporated within the system but also on the characteristics of other components such as 
nanocarrier size. In fact, even a small variation in physicochemical characteristics of the 
system may have a significant impact on the performance of the nanomedicine. Accurate and 
detailed characterisation of these systems is therefore critical in the development and clinical 
use of nanomedicines to ensure safe use and reproducibility.   
 
 
Characterisation of NP size 
There are several methods available to determine NP size and some of these will be 
discussed below (for a more comprehensive review on the topic, the reader is referred to 15). 
Note that each technique has its strengths and weaknesses, which have to be considered 
when characterising NPs. The application of a particular method depends on many factors, 
including the anticipated NP size range, mono- and polydispersity and NP material. Overall, it 
is recommended that different NP sizing methods are employed to ensure robustness, 
especially when considering the importance on biological response mentioned above. 
 
Dynamic light scattering (DLS)  
DLS is one of the most commonly used techniques for particle size measurement. This 
measures the hydrodynamic diameter of a particle via a laser beam that is scattered by the 
NPs in a suspension or solution. The Brownian motion of particles causes random 
fluctuations in the intensity of the scattered light around a mean value, used to determine the 
particle diffusion coefficient, which is related to its hydrodynamic radius via the Stokes–
Einstein relationship 15.  
 
DLS is typically used to measure NPs in the 1 nm - 500 nm range, although some systems 
claim a range of 0.3 nm – 10 µm. While a user-friendly technique, the analysis of multimodal 
particle size distribution is problematic with DLS 16. This is because the results are strongly 
biased in the presence of a small fraction of large particles as the signal intensity of a 
spherical particle with a radius r is proportional to its diameter to the power of 6. To exemplify, 
when a mixture of 5 and 50 nm NPs is measured, the signal of 5 nm particles is masked by 
that of 50 nm NPs, with the latter scattering 106 as much light. Consequently, average particle 
size values determined by DLS are biased. DLS therefore is best suited to measure the size 
of monodisperse NP samples. 
 
Electron Microscopy 
Electron microscopy (EM) uses electron beams to visualise NPs. The use EM is 
advantageous because it provides information on size and shape (morphology) in one 
analysis by direct visualisation. In scanning electron microscopy (SEM) electrons come from 
the sample surface, whereas in transmission electron microscopy (TEM) electrons pass 
through the sample. TEM has a superior resolution to SEM and is usually employed to study 
NP morphology. Due to image contrast, TEM is most suitable for particles containing heavier 
atoms such as gold and silver NPs. TEM, however, is a laborious technique and therefore is 
not suited to routine size measurements of large numbers of NP samples, but is usually 
reserved for morphological characterisation. 
 
Differential Centrifugal Sedimentation 
Differential Centrifugal Sedimentation (DCS) is based on the principle that with particles of the 
same density, larger particles sediment faster than smaller particles. Although most NPs do 
not sediment through simple gravitation (due to small size), their sedimentation can be 
induced by centrifugation. The disc centrifuge contains a hollow, optically clear disc, which 
has a central opening. The disc rotates at a known speed ranging from 600-24000 RPM. The 
empty spinning disc chamber is partly filled with liquid, which forms a liquid ring with a density 
gradient. The central opening is used to inject the sample for analysis. DCS gives a very high 
resolution and different nanoparticulate species of < 5% difference in diameter can be 
resolved completely. However, analysis times for smaller particle (< 50 nm) are long. 
 
DCS has recently been used to measure the change in size of gold NPs by changing ligand 
shells 17. For gold–polyamide functionalised NPs, a shift of 0.5 nm in the particle diameter 
was reported following functionalisation and in case of NP functionalisation with a larger 
molecular weight entity, namely single stranded DNA, this shift amounted to 2.1 nm (Figure 
1). This is therefore an example of the high-resolution NP sizing offered by this technique, 
which can be used to characterise NP, even following functionalisation or surface decoration 
with species with slight variations in molecular weight. The use of DCS to measure the size of 
ligand modified gold NPs was also recently reported Krpetic et al. 18. In this study, ligand 
shells were composed of polyethylene glycol-substituted alkane thiol of different chain length, 
or oligopeptides. DCS was highly sensitive to small changes in the thickness of particles due 
to the change in ligand shell, successfully measuring variations in the thickness of ligand 
shells on particles amounting to as little as 0.1 nm.  
 
 
 
Figure 2: Particle size distributions gold NPs functionalised with a) polyamide (‘Au-PA’) and b) single 
stranded DNA (‘Au-ssDNA’), compared to the original particle size distribution of gold-citrate (‘Au-
Citrate’) NPs.  
 
 
Nanoparticle Tracking Analysis 
Nanoparticle Tracking Analysis (NTA) is a technology that enables simultaneous visualisation 
and multi-parameter analysis of NPs, relating the rate of Brownian motion to particle size. The 
particles are visualised based on the light they scatter when illuminated by laser light. Unlike 
DLS, this technique has the ability to visualise individual particles in solution (each scattering 
source is tracked separately), then analyse for size (determined using the Stokes–Einstein 
equation) and count/concentration, both under scatter and fluorescence mode. Counting 
individual particles is useful when dealing with polydisperse samples, although NTA is still 
unable to separate fractions of particles with relative size difference of less than 50%. Filipe et 
al. compared NTA with DLS using polystyrene beads 19 and reported that the main advantage 
of NTA is its unbiased peak resolution of polydisperse samples, which was not possible to 
achieve with DLS (Figure 3). 
 
  
 
Figure 3. Size distribution from NTA and DLS measurements of mixtures of monodisperse polystyrene 
beads (middle panels) with the corresponding NTA video frame (left panels) and 3D graph (size vs. 
intensity vs. concentration; right panels). a) 60-nm/100-nm beads at a 4:1 number ratio; b) 100-nm/200-
nm beads at a 1:1 number ratio; c) 200-nm/400-nm beads at a 2:1 number ratio; d) 400-nm/1,000-nm 
beads at a 1:1 number ratio. Taken from Filipe et al. 19. 
 
Characterisation of NP surface 
Surface charge: Zeta (ζ) potential  
The surface charge of NPs is very important in drug delivery because it influences the 
interaction with the biological system, as well as the interaction with other species (including 
neighbouring NPs) in the suspension. Measurement of the ζ potential provides information on 
the net charge a NP has and therefore gives an indication of the electrostatic charge 
repulsion or attraction between particles in a liquid suspension. The ζ potential is usually 
measured by application of an electric field to the sample and measuring the velocity at which 
charged species move toward the electrode 15. ζ potential is generally a good measure of the 
stability of particles in the suspension as a large repulsion (high ζ potential) between particles 
means that they will stay away from each other (less chance of aggregation), which is 
generally aimed for nanosystems in drug delivery, and with weaker repulsion the likelihood of 
particles coming together (producing aggregates) is higher. 
 
The charge on the surface of particles and properties of the suspension diluent determine the 
zeta potential. The change in pH and the ionic strength of diluent will affect particle ζ 
potential. ζ potential measurements are therefore highly sensitive to sample suspension 
properties and can be used to determine optimum dispersion protocols and to study the 
stability of samples under changing conditions. It is recommended that ζ potential 
measurements of NPs are conducted in relevant biological media/solutions simulating the 
environment within which they interact with the biological systems.  
 
Surface chemistry 
The importance of NP surface chemistry in determining their biological response is 
increasingly being recognised, although the area remains somewhat poorly understood. A 
number of different surface-analysis techniques can be useful for NP surface 
characterisation, including electron spectroscopies (Auger electron spectroscopy [AES] and 
X-ray photoelectron spectroscopy [XPS], the latter possibly being the most widely used 
surface spectroscopy), ion-based methods (secondary ion mass spectrometry [TOF-SIMS] 
and low energy ion scattering [LEIS]) and scanning probe microscopy (atomic force 
microscopy [AFM] and scanning tunneling microscopy [STM]). For a comprehensive review 
on the usefulness of these techniques in NP surface chemical analysis the reader is referred 
to 20.  
 
NP changes within the biological environment 
In a complex biological environment nanocarriers may undergo a complete transformation in 
terms of size and surface characteristics. The colloidal stability of NP is influenced by many 
factors such as the ionic strength, pH and composition of the solution. The formation of a 
protein corona, which consists of plasma proteins such as albumin as a major component 21-
24, may significantly alter NP characteristics, including size and surface charge (and therefore 
the likelihood of aggregation). This in turn may completely change the nancarrier’s 
biocompatibility and biodistribution 25-26, as well as targeting capacity 27. The behavior of 
nanomedicines in the body is therefore an important point to consider when designing such 
systems as there is little point in formulating complex nanocarriers, for example with defined 
size and controlled surface distribution of targeting moieties/ligands, when such ‘designer’ 
nanocarriers morph into something entirely different in a biological environment. This point 
has recently been demonstrated with transferrin-functionalised NPs, the targeting ability of 
which disappears in a biological environment due to a biological media-originating surface-
adsorbed protein corona 27.  
 
With the above point in mind, characterisation of NPs should be conducted using appropriate 
techniques and for multiple parameters. This characterisation should be performed under 
physiologically relevant conditions reflecting the biological environment of the body in which 
the nanosystem is both distributed and exerts its therapeutic action. 
 
 
Conclusion 
The promise of nanomedicine has placed the development of cutting-edge nanosystems at 
the forefront of drug delivery research. The technology available to analyse NPs has 
improved considerably, which will no doubt advance our understanding of the influence of NP 
properties on their biological activity, as well as improve our ability to translate these systems 
into the clinic. Unfortunately, the science behind nanotechnology is much more complex than 
for small molecules and not all researchers developing various nanosystems will have all the 
tools enabling full characterisation in terms of size, shape, charge and surface chemistry, 
which is crucial as these properties govern the biological response of nanomaterials. 
Furthermore, this characterisation should take place within a biologically relevant 
environment. There is currently no single technique that can provide simultaneous information 
on all of these parameters (apart from instrumentation measuring both size and ζ potential), 
and even for determination of a single parameter such as size, different techniques exist, the 
use of which has to be carefully considered depending on the NP sample. The availability of 
instrumentation that can provide reliable multiparameter information, combined with ability to 
accommodate a range of different nanosystems (e.g. wide NP size range) and easy operation 
for users from different disciplines is highly desirable.  
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